IFNG and tuberculosis: The M72/AS01E–4 phase 2b vaccine trial, conducted in three tuberculosis-endemic countries in Africa (Kenya, South Africa, and Zambia), reported safety and efficacy in approximately 3500 HIV-negative adults with M tuberculosis infection, based on positive interferon-gamma release assay (IGRA) results.7